Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences' stock has experienced several notable events in the past six months. The company reported strong Q1 2026 financial results with net product sales exceeding $800 million, driven by INGREZZA and CRENESITY. Neurocrine Biosciences announced an agreement to acquire Soleno Therapeutics, including VYKAT XR. Several investment banks have updated their ratings and price targets for NBIX. As of May 8, 2026, NBIX stock was priced at $149.59, increasing by 7.3% since January 1st, 2026, and by 27.25% over the last 12 months.

For Neurocrine Biosciences' products, particularly INGREZZA, there have been nuanced seasonality considerations and headwinds in 1Q that have been problematic, but then ultimately lead to some tailwinds into 2Q in prior years. Historically, May has shown the highest probability of positive returns for NBIX, suggesting it may be an ideal month for investment.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders. The company operates within the Healthcare sector and the Biotechnology & Drugs industry. Neurocrine Biosciences has several FDA-approved treatments, including INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, ONGENTYS as an adjunctive therapy for Parkinson's disease, ORILISSA for endometriosis pain, ORIAHNN for heavy menstrual bleeding associated with uterine fibroids, CRENESITY for congenital adrenal hyperplasia, ALKINDI, and EFMODY. The company also maintains a robust pipeline with multiple compounds in mid-to late-phase clinical development across its core therapeutic areas.

Neurocrine Biosciences is headquartered in San Diego, California, United States. Its commercial products are primarily marketed in the United States. INGREZZA is marketed in Japan and other select Asian markets through a partnership. Clinical trials are conducted in North America, Europe, and Asia, leveraging strategic partnerships to expand its global reach.

Neurocrine Biosciences has maintained a positive brand reputation, marked by scientific advancements and industry recognition. The company announced the publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESITY and released new survey results highlighting the significant burden of tardive dyskinesia on employment. Neurocrine Biosciences initiated a Phase 1 clinical study evaluating NBIP-'2118. Forbes recognized Neurocrine Biosciences among its "Best Mid-Cap Companies (2026)" and "Most Trusted Companies in America (2025)" in the Drugs & Biotechnology industry.

Neurocrine Biosciences has significant institutional ownership. As of December 2025, 706 institutional investors held 95.1% of Neurocrine Biosciences' outstanding shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Dodge & Cox, JPMorgan Chase & Co, State Street Corp, Aqr Capital Management Llc, Renaissance Technologies Llc, Geode Capital Management, Llc, Price T Rowe Associates Inc /md/, and Wellington Management Group Llp. Overall, institutional ownership stands at approximately 97.98% to 98.77% of outstanding shares, while insider ownership is around 2.4%.